Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
The importance of educating patients about adverse effects of treatment
How can we assess quality of life in AML patients?
Issues in patient-physician communication in CLL patients
Novel agents in CLL: the importance of affordability